Abiopharma

🔍 Shulman Joseph (Executive)

Company: RHYTHM PHARMACEUTICALS, INC. (RYTM)

Report Date: 2025-08-21

Detailed Transactions and Holdings:

• Acquired 4,188 shares of Common Stock at $27.35 per share (Direct)
  Date: 2025-08-21 | Code: M | equity_swap_involved: 0 | shares_owned_after: 12,697.00 | transaction_form_type: 4
• Sold 4,188 shares of Common Stock at $100.0694 per share (Direct)
  Date: 2025-08-21 | Code: S | equity_swap_involved: 0 | shares_owned_after: 8,509.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Sold 4,188 shares of Stock Options (Right to Buy) at $27.35 per share (Derivative)
  Date: 2025-08-21 | Code: M | Expires: 2033-01-31 | equity_swap_involved: 0 | shares_owned_after: 18,844.00 | transaction_form_type: 4 | Footnotes: F3

Footnotes:

• F1: The sale reported in this Form 4 was effected pursuant to Rule 10b5-1 instruction adopted on August 8, 2024.
• F2: The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $100.00 to $100.30 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
• F3: The stock options were granted on February 1, 2023. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date.